Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral HIV Pre-Exposure Prophylaxis: A Mathematical Model

View ORCID ProfileKevin M. Maloney, Adrien Le Guillou, Robert A. Driggers, Supriya Sarkar, Emeli J. Anderson, View ORCID ProfileAmyn A. Malik, View ORCID ProfileSamuel M. Jenness
doi: https://doi.org/10.1101/19012443
Kevin M. Maloney
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin M. Maloney
  • For correspondence: kevin.maloney@emory.edu samuel.m.jenness@emory.edu
Adrien Le Guillou
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
2Department of Research and Public Health, Reims Teaching Hospitals, Robert Debré Hospital, Reims, France, 75019
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Driggers
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supriya Sarkar
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
3ViiV Healthcare, Research Triangle, NC, USA, 27709
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emeli J. Anderson
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amyn A. Malik
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
4Yale Institute for Global Health, New Haven, CT, USA, 06510
5Yale School of Medicine, New Haven, CT, USA, 06510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amyn A. Malik
Samuel M. Jenness
1Department of Epidemiology, Emory University, Atlanta, GA, USA, 30322
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel M. Jenness
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) is reportedly efficacious, although full trial results have not been published. We used a dynamic network model of HIV transmission among men who have sex with men (MSM) to assess the population impact of LAI-PrEP when available concurrently with daily-oral (DO) PrEP.

Methods The reference model represents the current HIV epidemiology and DO-PrEP coverage (15% among indicated) among MSM in the southeastern US. Primary analyses investigated varied PrEP uptake and proportion selecting LAI-PrEP. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and LAI-PrEP persistence relative to DO-PrEP.

Results Compared to the reference scenario, if 50% chose LAI-PrEP, 4.3% (95% SI: −7.3%, 14.5%) of infections would be averted over 10 years. LAI-PrEP impact is slightly greater than the DO-PrEP only regimen based on assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% (95% SI: 6.7%, 26.4%) of infections would be averted. The highest population-level impact occurred when LAI-PrEP uptake and persistence improved.

Conclusions If LAI-PrEP replaces DO-PrEP, its availability will modestly improve the population impact. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage, or if persistence is greater for LAI-PrEP.

Summary Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) will modestly decrease HIV incidence if it replaces daily-oral PrEP use among men who have sex with men. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage.

Competing Interest Statement

S.S. is an employee of ViiV Healthcare, which owns the patent for cabotegravir.

Funding Statement

This work was supported by National Institutes of Health grants R21 MH112449, R01 AI138783, and P30 AI050409 (Emory University Center for AIDS Research).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Reviewer suggestions/comments

Data Availability

This work was a simulation of disease transmission and does not represent analysis of primary data. The simulation parameters were derived from a variety of published data sources and referenced throughout the manuscript as necessary.

https://github.com/EpiModel/injectable-prep

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral HIV Pre-Exposure Prophylaxis: A Mathematical Model
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral HIV Pre-Exposure Prophylaxis: A Mathematical Model
Kevin M. Maloney, Adrien Le Guillou, Robert A. Driggers, Supriya Sarkar, Emeli J. Anderson, Amyn A. Malik, Samuel M. Jenness
medRxiv 19012443; doi: https://doi.org/10.1101/19012443
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral HIV Pre-Exposure Prophylaxis: A Mathematical Model
Kevin M. Maloney, Adrien Le Guillou, Robert A. Driggers, Supriya Sarkar, Emeli J. Anderson, Amyn A. Malik, Samuel M. Jenness
medRxiv 19012443; doi: https://doi.org/10.1101/19012443

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11639)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4654)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)